Engineered ACE2 receptor traps potently neutralize SARS-CoV-2
Open accessPublished version of a preprint
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Significance: During the ongoing COVID-19 pandemic, protein engineering offers a rapid and powerful approach for building therapeutics to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. We use computational design, affinity maturation, and fusion to dimerization domains to engineer “receptor traps” based on wild-type angiotensin-converting enzyme II (ACE2), the target for viral spike-mediated SARS-CoV-2 entry into cells. The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases. ACE2 receptor traps have large binding interfaces and block the entire receptor binding interface, limiting the potential impact of viral escape mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we established an in silico benchmark test (Supplementary Table 9) comprising 25 motif-scaffolding design problems addressed in six recent publications encompassing several design methodologies4,5,29,38–40”
From De novo design of protein structure and function with RFdiffusion (2023) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · cited 1×
“Furthermore, the three RBDs in the spike trimer can independently bind ACE2 (35, 36).”
BackgroundStructure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 5,040
Self-citationStructural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661 · cited 1×
“High-resolution ACE2–RBD structures (22, 23) show a large, flat binding interface primarily comprising the N-terminal helices of ACE2 (residues 18 to 90), with secondary interaction sites spanning residues 324 to 361 (Fig.”
BackgroundStructural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.-Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.045 · Cited by 2,892 · cited 2×
“High-resolution ACE2–RBD structures (22, 23) show a large, flat binding interface primarily comprising the N-terminal helices of ACE2 (residues 18 to 90), with secondary interaction sites spanning residues 324 to 361 (Fig.”
BackgroundSelf-citationMonteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., Leopoldi, A., Garreta, E., Hurtado del Pozo, C., Prosper, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.004 · Cited by 2,122 · cited 1×
“APN01 is currently in phase 2 clinical trials in Europe for treatment of SARS-CoV-2 (14) (NCT04335136).”
BackgroundStructure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,031
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., So, R. T. Y., Lv, H., Mok, C. K. P., & Wilson, I. A. (2020) · Science · doi:10.1126/science.abb7269 · Cited by 1,463
Remdesivir for the Treatment of Covid-19 — Preliminary Report
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2022236 · Cited by 1,396
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc6952 · Cited by 1,385
Self-citationA human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
Self-citationBaum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020) · Science · doi:10.1126/science.abd0831 · Cited by 1,253
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
Wu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc2241 · Cited by 993
Human aminopeptidase N is a receptor for human coronavirus 229E
Yeager, C. L., Ashmun, R. A., Williams, R. K., Cardellichio, C. B., Shapiro, L. H., Look, A. T., & Holmes, K. V. (1992) · Nature · doi:10.1038/357420a0 · Cited by 941
‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
Ridgway, J. B. B., Presta, L. G., & Carter, P. (1996) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/9.7.617 · Cited by 810
A simple physical model for binding energy hot spots in protein–protein complexes
Kortemme, T., & Baker, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202485799 · Cited by 804
Self-citationBarnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795
Crawford, K. H. D., Eguia, R., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 776
Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase
Wang, Q., Wu, J., Wang, H., Gao, Y., Liu, Q., Mu, A., Ji, W., Yan, L., Zhu, Y., Zhu, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.034 · Cited by 776
Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D., Tong, P., Guo, D., Fu, L., Cui, Y., Liu, X., et al. (2013) · Cell Research · doi:10.1038/cr.2013.92 · Cited by 719
Liu, Z., Xiao, X., Wei, X., Li, J., Yang, J., Tan, H., Zhu, J., Zhang, Q., Wu, J., & Liu, L. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25726 · Cited by 691
Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
Chan, K. K., Dorosky, D., Sharma, P., Abbasi, S. A., Dye, J. M., Kranz, D. M., Herbert, A. S., & Procko, E. (2020) · Science · doi:10.1126/science.abc0870 · Cited by 632
Khan, A., Benthin, C., Zeno, B., Albertson, T. E., Boyd, J., Christie, J. D., Hall, R., Poirier, G., Ronco, J. J., Tidswell, M., et al. (2017) · Critical Care · doi:10.1186/s13054-017-1823-x · Cited by 602
Computational Alanine Scanning of Protein-Protein Interfaces
Kortemme, T., Kim, D. E., & Baker, D. (2004) · Science's STKE · doi:10.1126/stke.2192004pl2 · Cited by 585
Self-citationNeutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
Huo, J., Le Bas, A., Ruza, R. R., Duyvesteyn, H. M. E., Mikolajek, H., Malinauskas, T., Tan, T. K., Rijal, P., Dumoux, M., Ward, P. N., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0469-6 · Cited by 500
An improved yeast transformation method for the generation of very large human antibody libraries
Benatuil, L., Perez, J. M., Belk, J., & Hsieh, C.-M. (2010) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzq002 · Cited by 435
Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
Lei, C., Qian, K., Li, T., Zhang, S., Fu, W., Ding, M., & Hu, S. (2020) · Nature Communications · doi:10.1038/s41467-020-16048-4 · Cited by 392
Zhou, T., Tsybovsky, Y., Gorman, J., Rapp, M., Cerutti, G., Chuang, G.-Y., Katsamba, P. S., Sampson, J. M., Schön, A., Bimela, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.004 · Cited by 362
Haschke, M., Schuster, M., Poglitsch, M., Loibner, H., Salzberg, M., Bruggisser, M., Penninger, J., & Krähenbühl, S. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0072-7 · Cited by 361
Wu, K., Li, W., Peng, G., & Li, F. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908837106 · Cited by 355
Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
Huang, C. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.010 · Cited by 166
Li, Y., Wang, H., Tang, X., Fang, S., Ma, D., Du, C., Wang, Y., Pan, H., Yao, W., Zhang, R., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01283-20 · Cited by 149
An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis
Kariolis, M. S., Miao, Y. R., Jones, D. S., Kapur, S., Mathews, I. I., Giaccia, A. J., & Cochran, J. R. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1636 · Cited by 142
Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2
Mou, H., Quinlan, B. D., Peng, H., Liu, G., Guo, Y., Peng, S., Zhang, L., Davis-Gardner, M. E., Gardner, M. R., Crynen, G., et al. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009501 · Cited by 141
Guy, J. L., Jackson, R. M., Jensen, H. A., Hooper, N. M., & Turner, A. J. (2005) · FEBS Journal · doi:10.1111/j.1742-4658.2005.04756.x · Cited by 129
Strauch, E.-M., Bernard, S. M., La, D., Bohn, A. J., Lee, P. S., Anderson, C. E., Nieusma, T., Holstein, C. A., Garcia, N. K., Hooper, K. A., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3907 · Cited by 119 · cited 1×
“There are no Food and Drug Administration-approved examples of receptor traps as antiviral biologics (46, 47), although some have entered clinical trials for HIV treatment (48).”
BackgroundThe sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2Preprint
Procko, E. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.16.994236 · Cited by 99
A method for plasmid purification directly from yeast
Singh, M. V., & Weil, P. A. (2002) · Analytical Biochemistry · doi:10.1016/s0003-2697(02)00018-0 · Cited by 90
Ollikainen, N., de Jong, R. M., & Kortemme, T. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004335 · Cited by 83
Self-citationDeventer, J. A. V., & Wittrup, K. D. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-992-5_10 · Cited by 83
Recombinant CD4‐IgG2 in Human Immunodeficiency Virus Type 1–Infected Children: Phase 1/2 Study
Shearer, W. T., Israel, R. J., Starr, S. E., Fletcher, C. V., Wara, D. W., Rathore, M. H., Church, J. A., Deville, J. G., Fenton, T., Graham, B., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/317622 · Cited by 78
Sui, J., Deming, M., Rockx, B., Liddington, R. C., Zhu, Q. K., Baric, R. S., & Marasco, W. A. (2014) · Journal of Virology · doi:10.1128/jvi.02232-14 · Cited by 69
Design of a superior cytokine antagonist for topical ophthalmic use
Hou, J., Townson, S. A., Kovalchin, J. T., Masci, A., Kiner, O., Shu, Y., King, B. M., Schirmer, E. B., Golden, K., Thomas, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217996110 · Cited by 62
Limitations of yeast surface display in engineering proteins of high thermostability
Park, S., Xu, Y., Stowell, X. F., Gai, F., Saven, J. G., & Boder, E. T. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl003 · Cited by 60
Receptor subtype discrimination using extensive shape complementary designed interfaces
Dang, L. T., Miao, Y., Ha, A., Yuki, K., Park, K., Janda, C. Y., Jude, K. M., Mohan, K., Ha, N.-T., Vallon, M., et al. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0224-z · Cited by 51
Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies
Julian, M. C., Lee, C. C., Tiller, K. E., Rabia, L. A., Day, E. K., Schick, A. J., & Tessier, P. M. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv050 · Cited by 44
Lim, S., Glasgow, J. E., Interrante, M. V. F., Storm, E. M., & Cochran, J. R. (2017) · Biotechnology Journal · doi:10.1002/biot.201600696 · Cited by 43
Self-citationZhou, T., Tsybovsky, Y., Olia, A. S., Gorman, J., Rapp, M. A., Cerutti, G., Chuang, G.-Y., Katsamba, P. S., Nazzari, A., Sampson, J. M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.04.187989 · Cited by 43
Li, Y., Wang, H., Tang, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.10.032342 · Cited by 38
Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidityPreprint
Lui, I., Zhou, X. X., Lim, S. A., Elledge, S. K., Solomon, P. E., Rettko, N. J., Zha, B. S., Kirkemo, L. L., Gramespacher, J. A., Liu, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.21.109157 · Cited by 35
Self-citationMiao, X., Luo, Y., Huang, X., Lee, S. M.-Y., Yuan, Z., Tang, Y., Chen, L., Wang, C., Wu, F., Xu, Y.-F., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1804241 · Cited by 35
Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2Preprint
Mou, H., Quinlan, B. D., Peng, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.29.178459 · Cited by 28
Li, W., Drelich, A. K., Martinez, D. R., Gralinski, L. E., Chen, C., Sun, Z., Schäfer, A., Leist, S. R., Liu, X., Zhelev, D. V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.13.093088 · Cited by 25
Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cellsPreprint
Miersch, S., Ustav, M., Li, Z., Case, J. B., Ganaie, S. S., Matusali, G., Colavita, F., Lapa, D., Capobianchi, M. R., Novelli, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.05.137349 · Cited by 10
Kwong, P. (2020) · Data Archiving and Networked Services (DANS) · doi:10.17632/y2j4k2mkd6.1 · Cited by 6
Kwong, P. D. (2020) · Data Archiving and Networked Services (DANS) · doi:10.17632/y2j4k2mkd6 · Cited by 6
Zhou, T., Tsybovsky, Y., Gorman, J., Rapp, M., Cerutti, G., Chuang, G., Katsamba, P. S., Sampson, J. M., Schön, A., Bimela, J. S., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3717767 · Cited by 5
A novel biparatopic antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapyPreprint
Miao, X., Luo, Y., Huang, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.14.147868 · Cited by 2
Cited by
Watson, J. L., Juergens, D., Bennett, N. R., Trippe, B. L., Yim, J., Eisenach, H. E., Ahern, W., Borst, A. J., Ragotte, R. J., Milles, L. F., et al. (2022) · doi:10.1101/2022.12.09.519842 · Cited by 2,369
De novo design of protein structure and function with RFdiffusion
Watson, J. L., Juergens, D., Bennett, N. R., Trippe, B. L., Yim, J., Eisenach, H. E., Ahern, W., Borst, A. J., Ragotte, R. J., Milles, L. F., et al. (2023) · Nature · doi:10.1038/s41586-023-06415-8 · Cited by 2,325
Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants
Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636
Machine learning for functional protein design
Notin, P., Rollins, N., Gal, Y., Sander, C., & Marks, D. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02127-0 · Cited by 270
Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases
Meganck, R. M., & Baric, R. S. (2021) · Nature Medicine · doi:10.1038/s41591-021-01282-0 · Cited by 252
Metadata
- Authors
- Glasgow, A., Glasgow, J., Limonta, D., Solomon, P., Lui, I., Zhang, Y., Nix, M. A., Rettko, N. J., Zha, S., Yamin, R., Kao, K., Rosenberg, O. S., Ravetch, J. V., Wiita, A. P., Leung, K. K., Lim, S. A., Zhou, X. X., Hobman, T. C., Kortemme, T., & Wells, J. A.
- Affiliations
- University of California, San Francisco (US)
- University of Alberta (CA)
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158;
- Department of Medicine, University of California, San Francisco, CA 94143;
- Rockefeller University (US)
- Corresponding author
- Wells, James A.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-10-22
- Volume
- 117
- Issue
- 45
- Pages
- 28046-28055
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7668070
- OpenAlex
- W3093802804
- Cited by
- 251
- References
- 61
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 29 · 2023: 42 · 2022: 69 · 2021: 68 · 2020: 14
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- PubMed Central (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- HHS | NIH | National Institute of General Medical Sciences (1K99GM135529, OD022552)
- Damon Runyon Cancer Research Foundation (DRG-2297-17)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (U19AI111825)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- ACE2 receptor, SARS-CoV-2, spike protein receptor-binding domain, affinity maturation, yeast surface display, Fc fusion, viral entry inhibition, neutralizing antibodies, COVID-19 treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.